Claims
- 1. An MRI agent comprising:
a) a paramagnetic metal ion; b) a chelator; and c) a matrix metalloproteinase (MMP) active peptide, covalently attached to said chelator; such that upon interaction of said agent and an MMP, the T1 of said agent is decreased.
- 2. An MRI agent according to claim 1 wherein said chelator is DOTA.
- 3. An MRI agent according to claim 1 having the formula:
- 4. An MRI agent according to claim 1, having the formula:
- 5. An MRI agent according to claim 3 or 4, wherein said M is Gd(III).
- 6. An MRI agent according to claim 3 or 4, wherein X1 is selected from the group consisting of an aryl or alkyl group.
- 7. An MRI agent according to claim 6 wherein said alkyl is selected from the group consisting of substituted alkyl, heteroalkyl and substituted heteroalkyl.
- 8. An MRI agent according to claim 6 wherein said aryl is selected from the group consisting of substituted aryl, heteroaryl and substituted heteroaryl.
- 9. An MRI agent according to claim 3 or 4, wherein X2 is selected from the group consisting of an aryl group, an alkyl group, a carbohydrate group, a nucleic acid group, a lipid group, and combinations thereof.
- 10. An MRI agent according to claim 4, wherein X1 is —(CH2CO)—, Y1 is -Pro-Met- when n=2, Y2 is -Trp-Met-Arg when m=3, and p=0.
- 11. An MRI agent according to claim 4, wherein X1 is —(CH2CO)—, Y1 is -Met- when n=1, Y2 is -Trp-Met-Arg when m=3, and p=0.
- 12. An MRI agent according to claim 4, wherein X1 is —(CH2CO)—, n=0, Y2 is -Trp-Met-Arg when m=3, and p=0.
- 13. A method comprising administering an MRI agent of claim 1, 3 or 4 to a cell, tissue or patient and producing and magnetic resonance image of said cell, tissue or patient.
- 14. A method comprising administering an MRI agent of claim 1, 3 or 4 to a cell, tissue or patient under conditions wherein said MMP peptide interacts with an MMP such that the T1 of said agent is decreased, and producing and magnetic resonance image of said cell, tissue or patient.
- 15. A method comprising:
a) contacting an MRI agent of claim 1, 3 or 4 with an MMP such that the T1 of said MRI agent is decreased, b) producing and magnetic resonance image.
- 12. A method according to claim 14, wherein said MMP is MMP 7.
- 13. A method according to claim 14, wherein said M is Gd(III).
- 14. A method according to claim 14, wherein X1 is selected from the group consisting of an aryl or alkyl group selected from the group consisting of substituted alkyl, heteroalkyl, substituted heteroalkyl, substituted aryl, heteroaryl and substituted heteroaryl.
- 15. A method according to claim 14, wherein X2 is selected from the group consisting of an aryl group, an alkyl group, a carbohydrate group, a nucleic acid group, a lipid group, and combinations thereof.
- 16. A method according to claim 14, wherein X1 is —(CH2CO)—, Y1 is -Pro-Met- when n=2, Y2 is -Trp-Met-Arg when m=3, and p=0.
- 17. A method according to claim 14, wherein X1 is —(CH2CO)—, Y1 is -Met- when n=1, Y2 is -Trp-Met-Arg when m=3, and p=0.
- 18. A method according to claim 14, wherein X1 is —(CH2CO)—, n=0, Y2 is -Trp-Met-Arg when m=3, and p=0.
Parent Case Info
[0001] This application claims the benefit of the filing date of Ser. No. 60/421,470, filed Oct. 24, 2002, under 35 U.S.C. §119(e) and is a continuation in part of Ser. No. 09/715,859, filed Nov. 17, 2000, which claims the benefit of the filing date of Ser. No. 60/201,816, filed May 4, 2000, under 35 U.S.C. §119(e).
Provisional Applications (2)
|
Number |
Date |
Country |
|
60421470 |
Oct 2002 |
US |
|
60201816 |
May 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09715859 |
Nov 2000 |
US |
Child |
10693252 |
Oct 2003 |
US |